Pulmonary Vascular Program

Pulmonary Vascular Program

The Pulmonary Vascular Program at Cleveland Clinic consists of a team of 7 pulmonologists, 1 cardiologist, 2 advanced practice nurses, a nurse, a program coordinator, and 2 research coordinators. Additionally, as part of Cleveland Clinic, the program draws on expertise in cardiology, cardiothoracic surgery, lung transplantation, hepatology, liver transplantation, sleep medicine, rheumatology, hematology, and interventional radiology to provide a comprehensive and multidisciplinary approach to patient care. Active clinical and research programs are offered for all types of pulmonary hypertension, including idiopathic pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, hereditary hemorrhagic telangiectasia, portopulmonary hypertension, congenital heart disease, and pulmonary hypertension associated with the scleroderma spectrum of diseases and other connective tissue diseases. The program offers advanced hemodynamic evaluation including invasive cardiopulmonary exercise testing (i.e., simultaneous right heart catheterization and cardiopulmonary exercise testing) and maintains an Institutional Review Board-approved comprehensive registry.

The Pulmonary Vascular Program is involved in a wide range of research activities, from NIH-funded basic research and translational research to clinical trials of the latest therapies. Many patients referred to the program benefit from enrollment in 1 or more of these ongoing clinical trials and research studies.

Patients Entered in the Pulmonary Hypertension Registry (N = 2,673)
CategoryNumber of Patients
Pulmonary Arterial Hypertension
  • Idiopathic
  • Pulmonary veno-occlusive disease
  • Heritable
Associated with:
  • Connective tissue disease
  • Portal hypertension
  • Congenital heart disease
Left Heart Disease
  • Systolic dysfunction
  • Diastolic dysfunction
  • Valvular disease
Lung Disease and/or Hypoxia
  • Chronic obstructive pulmonary disease
  • Interstitial lung disease
  • Mixed restrictive/obstructive
  • Sleep-disordered breathing
  • Alveolar hypoventilation
Chronic Thromboembolic Pulmonary Hypertension396
Unclear or Multifactorial166
Pulmonary Artery Catheterization Volume

2014 - 2019

The number of pulmonary artery catheterizations (standard and with exercise) performed at the Respiratory Institute has increased each year and has nearly doubled since 2015.

Actual and Predicted Survival of Patients with Category 1 Pulmonary Arterial Hypertension (N = 1,026)


The graph shows the survival curve for patients with category 1 pulmonary arterial hypertension enrolled in Cleveland Clinic’s Pulmonary Hypertension Registry, compared with their predicted survival based on the NIH registry equation¹ and with survival in a large French registry.² For both comparisons, Cleveland Clinic patients had better than expected survival. For example, actual 3-year survival for Cleveland Clinic patients was 68.1%, compared with 51.4% predicted by the NIH equation and 56.2% in the French registry.

  1. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. Survival in patients with primary pulmonary hypertension; results from a national prospective registry. Ann Intern Med. 1991 Sep 1;115(5):343-349.
  2. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1;173(9):1023-1030.